Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Bkm120

Research Leaders

5 sponsors active, led by Yonsei University

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 2 (2)
Phase 3 (1)

Trial Status

Completed2
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT01884623Phase 3CompletedPrimary

Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer

NCT01449201Phase 2Completed

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

NCT01527877Phase 2Unknown

Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck

Showing all 3 trials

Research Network

Common Treatments

  • Bkm1201
  • Pf002998041
  • Cetuximab1
  • Methotrexate1

Active Sponsors

  • Yonsei University2
  • National Cancer Institute, France1
  • Merck Serono International SA1
  • Ligue contre le cancer, France1
  • Gustave Roussy, Cancer Campus, Grand Paris1

Top Investigators

Related Conditions

  • Head Neck Cancer Squamous Cell Metastatic2

Activity Timeline